{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Table 9:', 'Dose Schedule for Vd Arm Cycles 1 through 8; 3-Week (21-day) Cycle', 'Week 1', 'Week 2', 'Week 3', 'Day', 'Vd', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', 'Borta', 'X', 'X', 'X', 'X', 'Rest period', 'Dexb', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Abbreviations: BIW = twice weekly; Bort = bortezomib; Dex = dexamethasone; eCRF = electronic case report form; SC = subcutaneous; Sel = selinexor;', 'QIW', '=', '4', 'times', 'per', 'week; Vd = bortezomib plus low-dose dexamethasone.', \"a Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC BIW during Weeks 1 and 2 of each cycle, followed by a 10-day rest period. If the patient's weight\", 'fluctuates substantially from baseline (ie, >20%) during treatment, BSA should be recalculated.', 'b', 'Dexamethasone will be given as an oral 20 mg dose QIW (ie, a total of 80 mg weekly) during Weeks 1 and 2 of each cycle. For patients who develop partial', 'intolerance to glucocorticoids during the study (as determined by the Investigator), a dose reduction to a minimum dose of 10 to 12 mg dexamethasone BIW', \"(ie, a total of 20 to 24 mg weekly) is permitted after a clear documentation of intolerance. Any dose reductions should be documented in the patient's research\", 'record and the eCRF.', 'Table 10:', 'Dose Schedule for Vd Arm Cycles 9; 5-Week (35-day) Cycle', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5', 'Day', 'Vd', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', '32', '33', '34', '35', 'Borta', 'Rest period', 'Dexb', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Abbreviations: BIW = twice weekly; Bort = bortezomib; D = day; Dex = dexamethasone; eCRF = electronic case report form; QW = once weekly; SC =', 'subcutaneous;', 'Sel = selinexor; Vd = bortezomib plus low-dose dexamethasone.', \"a Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC QW during Weeks 1 through 4, followed by a 13-day rest period. If the patient's weight fluctuates\", 'substantially from baseline (ie, >20%) during treatment, BSA should be recalculated.', 'b Dexamethasone will be given as an oral 20 mg dose BIW (ie, a total of 40 mg weekly) during Weeks 1 through 5. For patients who develop partial intolerance', 'to glucocorticoids during the study (as determined by the Investigator), a dose reduction to a minimum dose of 10 to 12 mg dexamethasone BIW (ie, a total of', \"20 to 24 mg weekly) is permitted after a clear documentation of intolerance. Any dose reductions should be documented in the patient's research record and the\", 'eCRF.', 'Confidential', 'Page 32', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Table 11:', 'Dose Schedule for SdX Patients; 5-Week (35-Day) Cycle', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5', 'Day', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', '32', '33', '34', '35', 'Sda', '1', 'Sd Dose Schedule', 'Selb', 'X', 'X', 'Dexc', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Selinexor Dose Escalation for Cycles >3:', 'Only Considered for Patients Who Meet the Following 3 Criteria: 1) Do Not Achieve At Least a PR Within the First 2 Cycles on Sd, and', '2)', 'Are', 'Tolerating Sd Well at Dose Level 0, and 3) Do Not Have Any AEs Related to Study Treatment Grade >2 (NCI CTCAE v. 4.03) at the', 'Time', 'of', 'Dose', 'Escalation', 'Seld', 'X', 'X', 'X', 'X', 'X', 'Dexc', 'X', 'X', 'X', 'X', 'Abbreviations: AE = adverse event; BIW = twice weekly; BSA = body surface area; CTCAE = Common Terminology Criteria for Adverse Events;', 'D', '=', 'day;', 'Dex = dexamethasone; eCRF = electronic case report form; MM = multiple myeloma; NCI = National Cancer Institute; PR = partial response: QW = once weekly;', 'SC = subcutaneous; Sel = selinexor; Sd = selinexor plus low-dose dexamethasone.', \"a If the patient's weight fluctuates substantially from baseline (ie, >20%) during treatment, BSA should be recalculated.\", 'b', 'Selinexor will be given as a fixed oral 100 mg dose QW. In no case may the selinexor dose exceed 70 mg/m\u00b2 per dose for any patient.', 'c Dexamethasone will be given as an oral 20 mg dose BIW (ie, a total of 40 mg weekly). For patients who develop partial intolerance to glucocorticoids during', 'the study (as determined by the Investigator), a dose reduction to a minimum dose of 10 to 12 mg dexamethasone BIW (ie, a total of 20 to 24 mg weekly) is', \"permitted after a clear documentation of intolerance. Any dose reductions should be documented in the patient's research record and the eCRF.\", 'd Selinexor may be given as a fixed oral 60 mg dose BIW during Weeks 1 through 5 of Cycles >3.', 'Confidential', 'Page 33', 'Version 4.0']\n\n###\n\n", "completion": "END"}